Teva Kicks Off Trial To Revoke Bayer's Cancer Drug Patent

Law360, London (May 4, 2021, 6:36 PM BST) -- Generic-drug maker Teva opened a London trial Tuesday by telling the judge that its bid to revoke three patents for Bayer's liver and kidney cancer drug had been significantly narrowed to a validity challenge against one patent.

Daniel Alexander QC of 8 New Square also said in the High Court that he was happy to report that in the days just before the trial start, the two sides had whittled down the issues even further.

"So the case has essentially come down to a very conventional obviousness case on a pharmaceutical formulation," Alexander told High Court Judge James Mellor.

Teva Pharmaceuticals...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!